Query author contributions in Reactome

Reactome depends on collaboration between our curation team and outside experts to assemble and peer-review its pathway modules. The integration of ORCID within Reactome enables us to meet a key challenge with authoring, curating and reviewing biological information by incentivizing and crediting the external experts that contribute their expertise and time to the Reactome curation process. More information is available at ORCID and Reactome.

If you have an ORCID ID that is not listed on this page, please forward this information to us and we will update your Reactome pathway records.

Details on Person Anti-MET recombinant therapeutic antibodies bind MET

Class:Id	Reaction:9734070
_displayName	Anti-MET recombinant therapeutic antibodies bind MET
_doRelease	TRUE
_timestamp	2021-08-10 12:10:54
authored	[InstanceEdit:9734140] Orlic-Milacic, Marija, 2021-06-15
compartment	[Compartment:984] extracellular region [Compartment:876] plasma membrane
created	[InstanceEdit:9734089] Orlic-Milacic, Marija, 2021-06-15
edited	[InstanceEdit:9750145] Orlic-Milacic, Marija, 2021-08-10
input	[CandidateSet:9734118] Anti-MET MAbs [extracellular region] [EntityWithAccessionedSequence:419603] MET [plasma membrane] [Homo sapiens]
isChimeric	FALSE
literatureReference	[LiteratureReference:9734090] Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent [LiteratureReference:9734111] LY2875358, a neutralizing and internalizing anti-MET bivalent antibody, inhibits HGF-dependent and HGF-independent MET activation and tumor growth [LiteratureReference:9734120] Depleting MET-Expressing Tumor Cells by ADCC Provides a Therapeutic Advantage over Inhibiting HGF/MET Signaling [LiteratureReference:8875387] Cbl-independent degradation of Met: ways to avoid agonism of bivalent Met-targeting antibody [LiteratureReference:9734106] Met degradation by SAIT301, a Met monoclonal antibody, reduces the invasion and migration of nasopharyngeal cancer cells via inhibition of EGR-1 expression
modified	[InstanceEdit:9734143] Orlic-Milacic, Marija, 2021-06-15 [InstanceEdit:9750145] Orlic-Milacic, Marija, 2021-08-10 [InstanceEdit:9750148] Orlic-Milacic, Marija, 2021-08-10 [InstanceEdit:9830342] Matthews, Lisa, 2023-03-08
name	Anti-MET recombinant therapeutic antibodies bind MET
output	[Complex:9734108] Anti-MET MAbs:MET [plasma membrane] [Homo sapiens]
releaseDate	2021-09-15
reviewed	[InstanceEdit:9750147] Kadambat Nair, Sisira, 2021-08-05
reviewStatus	[ReviewStatus:9821382] five stars
species	[Species:48887] Homo sapiens
stableIdentifier	[StableIdentifier:9734133] R-HSA-9734070.2
summation	[Summation:9734142] Recombinant monoclonal anti-MET therapeutic antibodies are e...
(hasEvent)	[Pathway:9734091] Drug-mediated inhibition of MET activation [Homo sapiens]
[Change default viewing format]

No pathways have been reviewed or authored by Anti-MET recombinant therapeutic antibodies bind MET (9734070)